<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161822</url>
  </required_header>
  <id_info>
    <org_study_id>2014-03-056</org_study_id>
    <nct_id>NCT02161822</nct_id>
  </id_info>
  <brief_title>Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients</brief_title>
  <official_title>A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are widely used as lipid-lowering agents to lower cardiovascular risk with a
      favorable safety profile. In our recent in vitro study, the addition of simvastatin to
      chemoradiotherapy with 5-FU showed synergistic anticancer effect in various colon cancer
      cells (unpublished data). So we planned this study to investigate the synergistic effect of
      simvastatin combined with capecitabine and radiotherapy in locally advanced rectal cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary Objective: pathologic complete response rate

        2. Secondary Objectives:

             1. rate of sphincter-sparing surgical procedure

             2. rate of R0 resection

             3. disease-free survival

             4. overall survival

             5. pattern of failure

             6. safety and toxicity

             7. lipid lowering effect of simvastatin
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>average of 5 weeks</time_frame>
    <description>pathologic complete response ratewill be shown with 95% confidence intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of sphincter-sparing surgical procedure</measure>
    <time_frame>average of 5 weeks</time_frame>
    <description>rate of sphincter-sparing surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of R0 resection</measure>
    <time_frame>average of 5 weeks</time_frame>
    <description>rate of R0 resection (N-60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>assessed up to 60 months</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>assessed up to 60 months</time_frame>
    <description>Time from randomization to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pattern of failure</measure>
    <time_frame>assessed up to 60 months</time_frame>
    <description>Sphincter preservation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and toxicity</measure>
    <time_frame>assessed up to 6 months</time_frame>
    <description>Response rate according to RECIST 1,1 guideline will also be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid lowering effect of simvastatin</measure>
    <time_frame>assessed up to 6 months</time_frame>
    <description>Total cholesterol, LDL-cholesterol records. (2weeks)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Adenocarcinoma of Rectum</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm : Simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 80mg qd for 5weeks</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed adenocarcinoma of rectum

          -  AJCC/UICC clinical stages of cT3-4 or cN+

          -  age â‰¥ 20 years

          -  ECOG performance status 0-1

          -  No prior chemotherapy and radiotherapy

          -  Adequate major organ functions as following:

          -  Written informed consent

          -  Willing and able to comply the protocol

        Exclusion Criteria:

          -  Prior statins therapy within 1-year from the date of study entry

          -  Uncontrolled or severe cardiovascular disease :

        New York Heart Association class III or IV heart disease Unstable angina or myocardial
        infarction within the past 6 months History of significant ventricular arrhythmia requiring
        medication with antiarrhythmics or significant conduction system abnormality.

          -  Past or current history (within the last 5 years prior to treatment start) of other
             malignancies except rectal cancer (Patients with curatively treated basal and squamous
             cell carcinoma of the skin or in situ carcinoma of the cervix are eligible)

          -  Uncontrolled systemic illness such as DM, hypertension, hypothyroidism and infection

          -  Pregnant nursing women (women of reproductive potential have to agree to use an
             effective contraceptive method)

          -  Patients with CPK &gt; 5 X ULN at baseline

          -  Concomitant use with clarithromycin, erythromycin, itraconazole, ketoconazole,
             nefazodone, telithromycin, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>woon ki kang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Ki Kang, MD</last_name>
    <email>wonki.kang@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Ki Kang, MD</last_name>
      <email>wonki.kang@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Won Ki Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ki Kang</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <keyword>locally advanced rectal cancer, neoadjuvant chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

